50BA Stock Overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bicycle Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.80 |
| 52 Week High | US$39.20 |
| 52 Week Low | US$15.20 |
| Beta | 0.77 |
| 1 Month Change | 1.57% |
| 3 Month Change | -11.03% |
| 1 Year Change | -29.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 50BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -4.1% |
| 1Y | -29.9% | 2.8% | -9.5% |
Return vs Industry: 50BA underperformed the German Biotechs industry which returned 2.8% over the past year.
Return vs Market: 50BA underperformed the German Market which returned -9.5% over the past year.
Price Volatility
| 50BA volatility | |
|---|---|
| 50BA Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 9.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 50BA is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 50BA's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 236 | Kevin Lee | https://www.bicycletherapeutics.com |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.
Bicycle Therapeutics plc Fundamentals Summary
| 50BA fundamental statistics | |
|---|---|
| Market Cap | €592.61m |
| Earnings (TTM) | -€105.05m |
| Revenue (TTM) | €13.48m |
44.0x
P/S Ratio-5.6x
P/E RatioIs 50BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 50BA income statement (TTM) | |
|---|---|
| Revenue | US$14.46m |
| Cost of Revenue | US$81.61m |
| Gross Profit | -US$67.15m |
| Other Expenses | US$45.57m |
| Earnings | -US$112.72m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.75 |
| Gross Margin | -464.26% |
| Net Profit Margin | -779.35% |
| Debt/Equity Ratio | 11.2% |
How did 50BA perform over the long term?
See historical performance and comparison